Stock listing
Frankfurt:8EV TheraCryf PLC Aktie
German listing (Frankfurt) of TheraCryf PLC · home listing LSE:TCF
Follow TheraCryf PLC into a list and get an email when it puts out news.
Share price · FWB:8EV
€0.0005 EUR 0.0000 (0.0%)
Close on Nov 20, 2026
- Day range
- €0.0005 – €0.0005 EURNov 20, 2026
- Market cap
- €5.29M EURAt the close on Nov 20, 2026 · price × 10.58B shares outstanding
- 52-week range
- €0.0005 – €0.0010 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €0 EURMedian day 0 shares · 34 days with no trades · last 3 months, Aug 21, 2026 – Nov 4, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:TCF · Home | 0.165p GBX (pence) | 0.000 (0.0%) | 41,237 | 0.165p | 0.165p | 0.161p | 0.165p | Close on Nov 20, 2026 |
| Frankfurt:8EV | €0.0005 EUR | 0.0000 (0.0%) | — | €0.0005 | €0.0005 | €0.0005 | €0.0005 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 21, 2026 – Nov 4, 2026 · FWB:8EV · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 2,400 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 |
- Ticker
- Frankfurt:8EV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 18, 2026
Ethics submission for Ox-1 Phase 1 study
Latest earnings call · Oct 20, 2026
TheraCryf (LSE:TCF) — Update on the Ox-1 programme
Replay and transcript
Latest deck · Sep 7, 2026
Shareholder Meeting (September 2026)
Shareholder meeting · 14 slides
Latest news
Result of Annual General Meeting
Oct 22, 2026
Closed €0.0010 (0.0%) on Oct 22, 2026
Ox-1 Preclinical Data Package Complete
Oct 19, 2026
Closed €0.0010 (0.0%) on Oct 19, 2026
Holding(s) in Company
Oct 13, 2026
Closed €0.0010 (0.0%) on Oct 14, 2026
Change of Nominated Adviser
Oct 9, 2026
Closed €0.0010 (0.0%) on Oct 9, 2026
Australian partner to progress Ox-1 Phase 1 trial
Oct 2, 2026
Closed €0.0010 (0.0%) on Oct 2, 2026
Posting of Annual Report and Notice of AGM
Sep 30, 2026
Closed €0.0010 (0.0%) on Sep 30, 2026
Final Results for the year ended 31 March 2026
Sep 28, 2026
Closed €0.0010 (0.0%) on Sep 30, 2026
Notice of Results and Investor Presentation
Sep 14, 2026
Closed €0.0010 (0.0%) on Sep 14, 2026
TheraCryf PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 236 in all · newest Nov 18, 2026 · oldest 2007
- Calls
- 12 calls with a replay · 12 with a transcript · latest Oct 20, 2026
- Decks
- 15 decks · latest Sep 7, 2026
Where TheraCryf PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:TCF · Home listing | LSE | United Kingdom | GBX |
| Frankfurt:8EV · This page | Frankfurt | Germany | EUR |
Valuation
Price/book 1.3× against a median of 1.2×: 5th lowest of 8 Biotechnology companies shown. Statements: Year to Mar 31, 2026 · price Nov 20, 2026
- Enterprise value
- £2.01M GBP
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| TheraCryf PLC · LSE:TCF | US$4.64M | US$2.63M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Oncodesign Precision Medicine S.A. · EURONEXT:ALOPM | US$5.04M | US$8.61M | 0.8× | 30.0× | 0.9× | 1.2× | n/a | 1.6× | n/a |
| Patrys Limited · ASX:PAB | US$4.96M | US$4.47M | n/a | 8.2× | n/a | 10.2× | −363.7% | 0.0× | n/a |
| Invex Therapeutics Ltd. · ASX:IXC | US$4.86M | US$2.20M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Can-Fite BioPharma Ltd. · TASE:CANF | US$4.86M | −US$2.14M | n/a | −5.3× | n/a | 1.0× | n/a | 0.0× | n/a |
| Zenith Capital Corporation · OTC:ZHCLF | US$4.83M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.06 |
| NFL Biosciences SA · EURONEXT:ALNFL | US$4.71M | US$5.36M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pulmatrix, Inc. · NASDAQ:PULM | US$4.64M | US$3.24M | n/a | n/a | n/a | 3.5× | n/a | 0.0× | 0.33 |
| AIM ImmunoTech Inc. · AMEX:AIM | US$4.57M | −US$937,186 | n/a | −10.3× | n/a | 0.7× | n/a | 0.2× | 0.66 |
| Tissue Repair Ltd · ASX:TRP | US$4.40M | US$1.24M | n/a | 3.4× | n/a | 0.8× | −958.0% | 0.0× | n/a |
| Processa Pharmaceuticals, Inc. · NASDAQ:PCSA | US$4.37M | −US$175.8M | n/a | n/a | n/a | n/a | n/a | n/a | 1.60 |
| Median of the others | US$4.77M | US$2.20M | 0.8× | 3.4× | 0.9× | 1.2× | −660.9% | 0.0× | 0.50 |
Forecasts
Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.21 GBX · Analysts' mean
- EPS, year to Mar 2027
- -0.001 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Alastair Smith | Chief Executive Officer |
| Huw Jones | Chief Executive Officer |
| Toni Haenninen | Chief Financial Officer |
| Helen Kuhlman | Chief Operating Officer |
| Andy Thacker | Northstar Communications Investor Relations |
| Guy McDougall | Northstar Communications Investor Relations |
| Glen Clack | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Alastair Smith | Chief Executive Officer |
| Alan Barge | Non-Executive Director |
| Edward Wardle | Non-executive Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| TheraCryf (LSE:TCF) — Update on the Ox-1 programme | Tue, Oct 20, 2026 · 8:00 AM ET | Replay |
| TheraCryf (LSE:TCF) — Final Results for the year ended 31 March 2026 | Mon, Sep 28, 2026 · 8:00 AM ET | Replay |
| TheraCryf (LSE:TCF) — Investor Presentation | Fri, Apr 24, 2026 · 5:00 AM ET | Replay |
| TheraCryf (LSE:TCF) — Half year results for the six months to 30 September 2025 | Wed, Dec 03, 2025 · 6:00 AM ET | Replay |
| TheraCryf (LSE:TCF) — Ox-1 – A deep dive into TheraCryf’s addiction programme | Wed, Jun 11, 2025 · 6:30 AM ET | Replay |
| TheraCryf (LSE:TCF) — Half Year Results | Thu, Nov 28, 2024 · 6:00 AM ET | Replay |
| TheraCryf (LSE:TCF) — Research and Development Update | Thu, Jun 13, 2024 · 4:30 AM ET | Replay |
| TheraCryf (LSE:TCF) — Investor Presentation | Wed, Mar 20, 2024 · 6:00 AM ET | Replay |
| TheraCryf (LSE:TCF) — Post-AGM Q&A | Thu, Jul 20, 2023 · 11:00 AM ET | Replay |
| TheraCryf (LSE:TCF) — Preliminary pharmacokinetic results from Phase 1b study of new SFX-01 tablet formulation | Thu, Mar 23, 2023 · 10:00 AM ET | Replay |
All 12 calls
| Call | When | Status |
|---|---|---|
| TheraCryf (LSE:TCF) — Interim Results 2022-23 | Thu, Dec 08, 2022 · 9:00 AM ET | Replay |
| TheraCryf (LSE:TCF) — Post AGM Presentation | Thu, Jul 21, 2022 · 10:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Dec 3, 2025 | +10.5% |
| Q4 2025 | Jun 2, 2025 | −3.6% |
| Q2 2025 | Nov 28, 2024 | −2.3% |
| Q2 2023 | Dec 5, 2022 | −7.0% |
| Q4 2022 | Jun 8, 2022 | 0.0% |
| Q2 2022 | Dec 8, 2021 | −5.6% |
| Q4 2021 | Jun 14, 2021 | −5.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (September 2026) | Shareholder meeting | 14 slides | Sep 7, 2026 |
| Investor Presentation (November 2025) | Investor deck | 21 slides | November 2025 |
| Investor Presentation (February 2025) | Investor deck | 22 slides | February 2025 |
| Investor Presentation (May 2024) | Investor deck | 12 slides | May 2024 |
| Evgen Pharma — Merger or Acquisition (April 2024) | Merger or acquisition | 12 slides | April 2024 |
| Evgen Pharma — Merger or Acquisition (March 2024) | Merger or acquisition | 13 slides | March 2024 |
| Evgen Pharma — Corporate Update (2023) | Corporate update | 13 slides | 2023 |
| Evgen Pharma — H1 2022 Earnings Presentation | Earnings | 10 slides | December 2022 |
| Evgen Pharma — Investor Presentation (February 2022) | Investor deck | 13 slides | February 2022 |
| Evgen Pharma — Shareholder Meeting (July 2021) | Shareholder meeting | 13 slides | Jul 13, 2021 |
All 15 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Evgen Pharma — Shareholder Meeting (July 2020) | Shareholder meeting | 20 slides | Jul 16, 2020 |
| Evgen Pharma — Shareholder Meeting (July 2019) | Shareholder meeting | 16 slides | Jul 18, 2019 |
| Evgen Pharma — FY2018 Earnings Presentation | Earnings | 41 slides | June 2018 |
| Evgen Pharma — Investor Presentation (May 2018) | Investor deck | 29 slides | May 2018 |
| Evgen Pharma — H1 2016 Earnings Presentation | Earnings | 34 slides | December 2015 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares (Placing Shares and Subscription Shares) Announced: about £1.05M · GBX 0.18 a share · Turner Pope +1 Dealers: Turner Pope (lead), Singer Capital Markets (co-lead) Buyers: Northern Standard Limited (138,888,888 Subscription Shares; 20.8% of Enlarged Share Capital following Admission); Dr Huw Jones (5,555,555 Subscription Shares); Toni Haenninen (via Borealito GmbH) (4,444,444 Subscription Shares); Dr Alastair Smith (13,888,888 Subscription Shares); Dr Nicholas Mallard (2,777,777 Subscription Shares); Dr Glen Clack (1,388,888 Subscription Shares); Dr Helen Kuhlman (3,333,333 shares) Insiders: Certain PDMRs to subscribe for an aggregate 28,055,552 New Ordinary Shares through the PDMR Subscription Use of proceeds: Complete clinic-enabling programme for Ox-1 addiction asset, apply for Phase 1 approval in Australia, and extend cash runway to end Q1 2027 | Aug 20, 2026 | US$1.43M |
| Private placement of new ordinary shares Update: £4.25M · £0.0025 a share · Turner Pope Investments (TPI) Limited Dealers: Turner Pope Investments (TPI) Limited (lead) Buyers: Tracarta Limited (£1,000,000 for 400,000,000 new Ordinary Shares); Dr Alastair Smith (4,000,000 Ordinary Shares); Dr Huw Jones; Toni Hänninen Insiders: Directors and PDMRs subscribing £28,000 for 11,200,000 new Ordinary Shares; a related party transaction Use of proceeds: Pre-clinical development of Ox-1 orexin-1 antagonist, SFX-01 tablet manufacturing, patent portfolio, consultants and general corporate purposes | Mar 7, 2025 | US$5.35M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 396.0K | 442.0K | 0 | 194.0K | ||||
| Cost of revenue | 16.0K | 2.11M | 11.0K | 13.0K | 16.0K | 3.39M | 21.0K | 21.0K | 21.0K | 17.0K |
| Gross profit | -16.0K | -2.11M | 385.0K | 429.0K | -16.0K | -3.19M | -21.0K | -21.0K | -21.0K | -17.0K |
| Research and development | 2.76M | 398.0K | 2.77M | 4.72M | 2.60M | 2.73M | 1.70M | 1.69M | 1.67M | 2.10M |
| Selling, general and administrative | 901.0K | 904.0K | 1.16M | 765.0K | 564.0K | 635.0K | ||||
| Operating income | -3.69M | -2.12M | -3.56M | -5.07M | -3.19M | -3.20M | -3.15M | -3.12M | -3.03M | -3.64M |
| Depreciation and amortization | 16.0K | 69.0K | 11.0K | 13.0K | 16.0K | 18.0K | 21.0K | 21.0K | 21.0K | 17.0K |
| EBITDA | -3.67M | -2.06M | -3.55M | -5.06M | -3.17M | -3.19M | -3.13M | -3.10M | -3.01M | -3.63M |
| Interest expense | 3.00K | |||||||||
| Income before tax | -3.57M | -2.08M | -3.57M | -5.01M | -3.17M | -3.21M | -3.17M | -3.12M | -3.03M | -3.64M |
| Income tax | -37.0K | 144.0K | -429.0K | -963.0K | -439.0K | -539.0K | -451.0K | -496.0K | -443.0K | -576.0K |
| Net income | -3.53M | -1.94M | -3.14M | -4.04M | -2.73M | -2.67M | -2.71M | -2.62M | -2.58M | -3.07M |
| Earnings per share, basic | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 471.0K | 2.11M | 2.00M | 5.00M | 4.51M | 5.59M | 4.13M | 2.03M | 3.63M | 3.86M |
| Short-term investments | 1.07M | 2.00M | 4.52M | 6.00M | ||||||
| Receivables | 747.0K | 404.0K | 497.0K | 1.02M | 483.0K | 652.0K | 531.0K | 589.0K | 463.0K | 692.0K |
| Inventory | -1.00K | |||||||||
| Current assets | 2.29M | 5.17M | 3.03M | 6.13M | 9.58M | 12.3M | 4.77M | 2.66M | 4.13M | 4.60M |
| Total assets | 4.81M | 7.63M | 3.06M | 6.17M | 9.64M | 12.4M | 4.86M | 2.76M | 4.26M | 4.74M |
| Accounts payable | 1.68M | 106.0K | 330.0K | 402.0K | 66.0K | 408.0K | 516.0K | 532.0K | 102.0K | 164.0K |
| Current liabilities | 1.69M | 1.66M | 721.0K | 833.0K | 411.0K | 607.0K | 653.0K | 688.0K | 389.0K | 514.0K |
| Total debt | 11.0K | |||||||||
| Total liabilities | 2.10M | 1.66M | 721.0K | 833.0K | 411.0K | 607.0K | 653.0K | 688.0K | 389.0K | 514.0K |
| Shareholders' equity | 2.72M | 5.97M | 2.34M | 5.34M | 9.23M | 11.8M | 4.20M | 2.08M | 3.87M | 4.23M |
| Shares outstanding | 2.15B | 538.3M | 274.9M | 274.9M | 274.9M | 147.0M | 131.2M | 97.3M | 79.9M | 74.2M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -2.55M | -2.37M | -3.00M | -4.03M | -2.56M | -2.93M | -2.58M | -2.29M | -2.34M | -3.19M |
| Capital spending | -17.0K | 0 | 0 | -1.00K | -3.00K | -5.00K | -1.00K | 0 | -7.00K | -76.0K |
| Free cash flow | -2.56M | -2.37M | -3.00M | -4.03M | -2.56M | -2.93M | -2.58M | -2.29M | -2.35M | -3.27M |
| Cash from investing | 916.0K | -2.08M | 4.52M | 1.48M | -6.00M | -1.00K | -7.00K | 1.93M | ||
| Cash from financing | -7.00K | 4.55M | 10.4M | 4.67M | 694.0K | 2.12M | ||||
| Change in cash | -1.64M | 105.0K | -3.00M | 490.0K | -1.08M | 1.46M | 2.10M | -1.59M | -233.0K | -1.26M |
Cap table
Built by 6ix from TheraCryf PLC’s releases · as of Aug 20, 2026
- Common shares
- 2,148,963,739
- Fully diluted
- 2,148,963,739
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,148,963,739 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,148,963,739 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alan Barge | Non-Executive Director · Since at least May 1, 2025 |
| Alastair Smith | Chief Executive Officer · Since at least Sep 28, 2026 |
| Andy Thacker | Northstar Communications Investor Relations · Since at least Oct 9, 2026 |
| Edward Wardle | Non-executive Director · Since at least Sep 28, 2026 |
| Glen Clack | Chief Medical Officer · Since at least Aug 20, 2026 |
| Guy McDougall | Northstar Communications Investor Relations · Since at least Oct 22, 2026 |
| Helen Kuhlman | Chief Operating Officer · Since at least Oct 22, 2026 |
| Huw Jones | Chief Executive Officer · Since at least Oct 22, 2026 |
| Toni Haenninen | Chief Financial Officer · Since at least Sep 28, 2026 |
Log in to ask 6ix AI your own questions about TheraCryf PLC.